Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00091741 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy Study of Etanercept (Enbrel) on the Response Rate of HIV-infected Subjects
A Phase 1 study, sponsored by Georgetown University.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00091741 is a Phase 1 study that has completed, run by Georgetown University. The registered enrollment target is 10 participants.
The verdict
NCT00091741, a Phase 1 study, has completed, sponsored by Georgetown University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of conducting this already-FDA approved Phase I clinical trial is to evaluate the safety and efficacy of etanercept (Enbrel) on the response rate in HIV-infected subjects who have failed to respond to conventional antiretroviral (HAART) therapy and for whom no alternative therapy exists. The greatest challenge faced by HIV-treating clinicians today is the management of virologic failure and metabolic complications of anti-HIV treatment. Treatment failure can occur because of non-compliance, drug discontinuation, lack of drug potency, inadequate drug plasma concentration or drug resistance. Of these, drug resistance remains the single most important reason for virological failure and rapidly limits treatment options.
Interventions
- DRUG Etanercept (Enbrel)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Est. Completion | 2004-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00091741
The ClinicalTrials.gov registry entry for NCT00091741 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Etanercept (Enbrel) is the first listed.
NCT00091741 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00091741 about?
NCT00091741 is a clinical study titled "Safety and Efficacy Study of Etanercept (Enbrel) on the Response Rate of HIV-infected Subjects". The purpose of conducting this already-FDA approved Phase I clinical trial is to evaluate the safety and efficacy of etanercept (Enbrel) on the response rate in HIV-infected subjects who have failed to respond to conventional antiretroviral (HAART) therapy and for whom no alternative therapy exists....
What is the current status of trial NCT00091741?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. Estimated completion is 2004-10.
What interventions are being tested in trial NCT00091741?
The interventions under investigation include: Etanercept (Enbrel) (DRUG).
Who is sponsoring clinical trial NCT00091741?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.